Thirty‐two patients with metastatic breast cancer who had not received prior chemotherapy for metastatic disease were entered into a trial of mitoxantrone 12 mg/m2 plus Cyclophosphamide 600 mg/m2 given at three weekly intervals. Thirty‐one patients are eligible for assessment. Response was seen in 65% (4/31 complete regression; 16/31 partial regression). Median duration of response was 6 months and median duration of survival was 10 months. Mitoxantrone + Cyclophosphamide appears to be an active combination in treatment of metastatic breast cancer.
|Original language||English (US)|
|Number of pages||4|
|State||Published - Oct 15 1986|
ASJC Scopus subject areas
- Cancer Research